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Abstract: This study assessed the efficacy, durability, and tolerability
of fluoxetine for hypochondriasis, a disorder for which controlled
pharmacological trials are scarce.
Fifty-seven patients with hypochondriasis were enrolled: 12
discontinued during the placebo run-in, and 45 were randomized to
either fluoxetine or placebo for 12 weeks (acute treatment). Responder
status was defined as a Clinical Global Impression rating for hypo-
chondriasis of much or very much improved. Secondary outcome
measures included severity of hypochondriasis, somatization, anxiety,
and depression. Responders to acute treatment entered a 12-week
maintenance phase to week 24. Sustained responders at week 24
entered a 12-week double-masked discontinuation phase. Primary
analysis used the intent-to-treat sample.
More patients responded with improvement in hypochondriasis
when given fluoxetine compared with placebo, starting at week 8
(50.0% vs 19.0%, P = 0.03) and continuing to week 12 (62.5% vs
33.3%, P = 0.05). Mean dose at week 12 dose was 51.4 mg (SD,
T23 mg). The acute treatment response was maintained to week 24
with more responders in the fluoxetine compared with the placebo
group (54.2% vs 23.8%, P = 0.04). Significant improvement was
not noted on the continuous secondary outcomes measures of
hypochondriasis, with the exception of the Clinical Global Impres-
sion hypochondriasis severity scale at week 24. Likelihood of
response was not associated with severity of psychiatric comorbid-
ity. Durability of response after controlled drug discontinuation
could not be reasonably assessed, given the small sample size of
patients who entered the discontinuation phase (n = 10). Fluoxetine
was well tolerated, with no significant differences in discontinuation
due to side effects between treatment groups.
Fluoxetine is a moderately effective and well-tolerated treatment
for hypochondriasis.
(J Clin Psychopharmacol 2008;28:638–645)
Hypochondriasis, a chronic and disabling disorder, affects4% to 6% of patients in primary care settings.1–4 Both
Diagnostic and Statistical Manual of Mental Disorders,
Revised Third Edition (DSM-III-R) and Diagnostic and
Statistical Manual of Mental Disorders, Fourth Edition
(DSM-IV) define hypochondriasis as a preoccupation with
the fear or belief that one has a serious disease based on a
misinterpretation of bodily symptoms that persists for at least
6 months despite appropriate medical evaluation or reassur-
ance and which causes either clinically significant distress or
functional impairment. These patients respond poorly to stan-
dard medical management, often receive unnecessary tests or
medical care, and are perceived by physicians as reluctant to
accept a psychotherapy referral.5,6
Despite its prevalence and adverse personal and public
health impact, hypochondriasis has only recently been the
subject of controlled treatment studies. These studies indicate
that cognitive behavioral therapy can be helpful for patients
with hypochondriasis.7,8 However, there has been only 1 prior
placebo-controlled pharmacotherapy study9; this study dem-
onstrated the short-term effectiveness of paroxetine, a selec-
tive serotonin reuptake inhibitor (SSRI), for the completer
sample but not for the intent-to-treat (ITT) sample. No study
has yet reported the durability of response to a pharmacol-
ogical agent among treatment responders, and there have
been no controlled studies of other medications.
This randomized, double-masked, placebo-controlled
clinical trial was conducted to evaluate both the short- and
long-term efficacy and tolerability of treatment with fluox-
etine for hypochondriasis. Fluoxetine was chosen for 3 rea-
sons. First, a serotonin reuptake inhibitor should be effective
for the obsessional aspects of hypochondriasis. Second, flu-
oxetine is generally well tolerated with few side effects.
Third, earlier uncontrolled research using fluoxetine indicated
that as many as 70% of patients are at least much improved
after 12 weeks of treatment.10
METHODS
Study Participants
Between 1993 and 2000, individuals with a history of
hypochondriasis between the ages of 18 and 75 years were
recruited from primary care clinic screenings, physician
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mailings, and media announcements. The study was approved
by the human subjects committees at the New York State
Psychiatric Institute and Columbia University. After complete
description of the study to the subjects, written informed
consent was obtained. Evaluation and outpatient treatment
were conducted at the New York State Psychiatric Institute, at
the Freedom From Fear Clinic in Brooklyn, NY (a free-
standing community mental health clinic), or at the Family
Medicine Center at St Joseph’s Medical Center in Stamford,
CT. Participants were eligible if they met the DSM-III-R
(later DSM-IV) criteria for hypochondriasis, had a severity of
hypochondriasis that was rated as at least Bmoderate[ on the
Clinical Global Impression–Severity scale of hypochondria-
sis,11 were willing to be free of psychiatric medications for
at least 2 weeks before randomization, and were able to
provide written informed consent. Excluded were participants
with other current primary Axis I psychiatric disorders, a
current Axis II diagnosis of antisocial personality disorder, a
lifetime psychotic or bipolar disorder, prominent suicidal
ideation within the preceding 6 months, an unstable major
medical illness, or an uncertain current medical condition.
For patients with a current medical problem, the patient’s
doctor had to agree that the medical problem was stable and
that the patient’s concerns about his/her medical problem
were excessive. Access to other physicians or health care
providers was not restricted during the treatment phase of
this study.
Study Design
Patients with a primary diagnosis of hypochondriasis
were enrolled in a 36-week trial, consisting of three 12-week
double-masked phases: acute (phase 1), maintenance (phase 2),
and discontinuation (phase 3) Before initial randomization, all
patients received single-masked placebo, 1 pill per day, for the
first 2 weeks of the study to exclude patients with poor
compliance or an early placebo response. Patients rated as
nonresponders by an independent evaluator (IE) at the end of
the placebo run-in phase were randomized to fluoxetine or
matching placebo capsules. Patients rated by the IE as
responders at the end of phase 1 (week 12) continued into
phase 2 while maintaining the same number of study pills.
Nonresponders at the end of phase 1 or patients who reverted to
nonresponse at the end of phase 2 (week 24) were removed from
the study and treated openly. Patients rated as responders at the
end of phase 2 entered the discontinuation phase, in which
patients on placebo continued on placebo, whereas patients on
fluoxetine were randomly assigned to either placebo or
continued fluoxetine (Fig. 1).
Acute Treatment
Dosing of fluoxetine and matching placebo started at
1 pill or 20 mg daily and increased by 20 mg/d every 2 weeks,
as needed and tolerated, to a maximum dose of 80 mg/d.
Patients met with a study psychiatrist weekly for the first
4 weeks and every 2 weeks thereafter. During each study
visit, the doctor reviewed the patient’s side effects using a
side effect checklist, reviewed illness-related experiences
using a daily diary, and adjusted medication dose accordingly.
Maintenance Phase
Responders at week 12 who agreed to continue in the
study continued on the same treatment and met with the
psychiatrist monthly.
Discontinuation Phase
At week 24, some patients on fluoxetine received a
week 24 randomization that required a switch to placebo.
This switch was done in a masked fashion without changing
the number of pills and without a taper. Other patients stayed
on the same treatment as in the maintenance phase. Monthly
study visits with the psychiatrist continued.
Randomization
Patients were assigned in a 1:1 ratio to oral fluoxetine
or a matching oral placebo pill using a computer-generated
randomization list. The randomization was stratified with
respect to current DSM Axis I comorbidity (none, major de-
pressive disorder, or dysthymia or other) and Axis II co-
morbidity (present/absent).
Masking
A research pharmacist, who had no contact with the
patient, prepared prescriptions. The treatment randomization
was masked to the patient and all clinical and research staff.
To avoid inadvertent unmasking, patients were reminded not
to discuss adverse events with the IEs.
Sample Size
A sample size of 56 randomized subjects provided a
power of 0.86 to detect a difference in responder rate at a




At the primary care clinic site, subjects were screened
for hypochondriasis using the Whiteley Index for hypochon-
driasis,12 with a score of 8 or more serving as the threshold to
be evaluated further. Patients calling from elsewhere were
screened over the telephone using the diagnostic criteria for
hypochondriasis. The research psychiatrist conducted an in-
person psychiatric and medical history to confirm that the
patient’s unexplained medical symptoms were indeed due to
hypochondriasis and not due to an unattended medical prob-
lem. The interview was followed by a physical examination
with electrocardiogram, urinalysis, and laboratory blood
work, as well as a comprehensive diagnostic assessment
using the Structured Clinical Interview for DSM-III-R (later
DSM-IV) (SCID I and SCID II). (Refer to Fig. 1 for
participant flow diagram.)
Outcome Measures
Participants were assessed before treatment and at
weeks 4, 8, 12, 24, and 36 by an IE for whom treatment
randomization was masked. Two IEs participated in this
study, each a research nurse with several years of experience
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in the evaluation of outcome in clinical trials. Interrater re-
liability meetings were held monthly to ensure concordance
between raters. The primary outcome measure was the Clin-
ical Global Impression13 of change in hypochondriasis as rat-
ed by the IE. A Bresponder[ was defined based on a rating of
Bvery much improved[ (virtual remission of hypochondriasis)
or Bmuch improved[ (clinically significant improvement).
The primary end point for the acute phase was week 12.
Other hypochondriasis-specific assessments included the IE-
administered measures (the Heightened Illness Concern
[HIC] Severity Scale11 and the Columbia Heightened Illness
Concern–Obsessive-Compulsive Scale [CHIC-OCS]), a
hypochondriasis-focused adaptation of the well-standardized
Yale-Brown Obsessive Compulsive Scale, an obsessive-
compulsive disorder [OCD] rating scale14) and the self-report
Whiteley Index.12 The HIC Severity Scale, the CHIC-OCS,
and the Whiteley Index were examined both as continuous
measures to describe magnitude of improvement at the end
of each phase compared with baseline and as categorical mea-
sures to identify patients who improved at least 25% over the
baseline score. Other psychopathology was assessed by the
Somatic Symptom Inventory (SSI),15,16 Beck Depression In-
ventory (BDI),17 the Hamilton Depression Scale (HAM-D)
(24 items),18 and the Hamilton Anxiety Scale (HAM-A).19
Statistical Analyses
The primary analysis involved the ITT sample, which
included all subjects who were randomized into phase 1.
Secondary analyses examined the response of subjects who
received at least 6 weeks of treatment (Bminimum-treatment
completers[) and subjects who completed all 12 weeks of
study medication (Bacute-phase completers[). For subjects
leaving the study before completion, ratings at the time of
termination or, if unavailable, their most recent postrandom-
ization ratings were used as their end-of-treatment assess-
ment. Patients for whom a postrandomization IE rating could
not be obtained (ie, in patients who dropped out in the first
3 weeks and would not return for a termination IE rating)
were considered nonresponders. Categorical outcome was
FIGURE 1. Flow diagram of the randomized fluoxetine study design.
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analyzed using W2 test for independence, and continuous
outcome was analyzed using 2-sample t tests to evaluate
percentage improvement compared with baseline scores.
To assess the effect of various baseline covariates
(depression [HAM-D, BDI], anxiety [HAM-A], somatization
[SSI], comorbid Axis I depressive disorder [DSM depression
or dysthymia], comorbid personality disorders [SCID II], and
duration of illness) on the treatment outcome, response status
was modeled as a function of treatment, a covariate, and
treatment-by-covariate interaction using logistic regression; if
a significant interaction effect was not found, we fitted a
model involving only main effects of treatment and the co-
variate; separate models were fit for each of the covariates.




Of 971 patients screened either over the telephone or in
person, 57 were eligible for the study, and 914 were not
eligible or not interested in research (Fig. 1). Most patients
were excluded because hypochondriasis was either not
present or not of sufficient severity (n = 761) or another
psychiatric disorder better accounted for the primary symp-
toms (n = 25).
Acute Phase
Enrollment
Of the 57 patients who entered the study, 12 were ex-
cluded before randomization during the 2-week placebo run-
in phase, 10 due to poor compliance and 2 due to a rapid
placebo response. Of the 45 randomized patients (the ITT
sample), 37 (82.2%) completed at least 6 weeks of phar-
macological treatment (minimum-treatment completers), and
32 (71.1%) completed the full 12 weeks of acute treatment
(acute-phase completers).
Description of the Randomized Sample
The average age was 39.5 years (SD, 11.2 years; range,
19–70 years), equally distributed by sex (20 men and 25 wom-
en). The sample was 84.2% white, 10.5% black, 1.8% Asian,
and 3.5% other. Ethnically, 45.6% were Hispanic, and 54.4%
were non-Hispanic. In respect to Axis I disorders, the study
sample had 28.9% with primary hypochondriasis alone, 48.9%
with primary hypochondriasis and a secondary depressive
disorder, and 22.2% with primary hypochondriasis and another
non–depression-related major Axis I disorder. On Axis II,
46.6% had at least 1 comorbid personality disorder. Among the
21 patients with personality disorders, the mean number of
Axis II disorders was 2.7 (SD, 1.9) with a range of 1 to 7. The
most common personality disorders among these 21 patients
were avoidant (42.9%), paranoid (38.1%), and borderline
(23.8%). Patients’ primary disease worry varied widely, but
most common among the 45 subjects was the fear or conviction
of having cancer (37.7%), heart disease (15.5%), and AIDS
(13.3%). On the HIC Severity Scale, 18.2% experienced severe
TABLE 1. Baseline Descriptors of the Randomized Sample
Fluoxetine
Group (n = 24)
Placebo
Group (n = 21)
Characteristics Mean SD Mean SD
Age, yrs 37.8 9.2 39.6 12.2
Age at onset, yrs 30.6 10.1 29.2 14.0
Duration of hypochondriasis, yrs 8.0 7.9 10.2 9.7
Whiteley Index 50.4 12.6 53.2 8.9
HIC Severity Scale 5.0 0.7 4.9 0.8
CHIC-OCS 19.1 7.0 17.7 6.4
SSI 58.3 17.1 67.4 19.7
BDI 16.4 12.7 16.4 11.1
HAM-D 14.8 5.8 12.5 6.4
HAM-A 15.5 6.6 13.9 5.1
n % n %
Female sex 12 50.0 13 61.8
Education
No more than high school 9 37.5 7 33.3
Post–high school education but
no degree
8 33.3 7 33.3
Degree or more 7 29.2 7 33.3
Frequency of doctor visits
<4 times in last year 6 25.0 5 23.8
4–11 times in last year 7 29.2 5 23.8
At least once a month 11 45.8 10 47.6
No. different doctors seen in last year
No more than 1 doctor 8 33.3 5 23.8
2–5 doctors 8 33.3 13 61.8
>5 different doctors 8 33.3 3 14.3
Axis I comorbidity
None 6 25.5 7 33.3
Major depression/dysthymia 14 58.3 8 38.1
Other 4 16.7 6 28.6
Axis II comorbidity
None 13 54.2 11 52.4
At least 1 DSM Axis II diagnosis 11 45.8 10 47.6
Note. All differences between groups were non-significant, P > 0.10.






Sample n % n % W2 P
ITT (n = 45)
Wk 4 9/24 37.5 6/21 28.6 0.40 0.53
Wk 8 12/24 50.0 4/21 19.0 4.68 0.03
Wk 12 15/24 62.5 7/21 33.3 3.8 0.05
Minimum
treatment (n = 37)
15/21 71.4 5/16 31.3 5.90 0.02
Acute-phase
completer (n = 32)
14/18 77.8 4/14 28.6 7.75 0.005
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or extreme hypochondriasis, 52.3% marked hypochondriasis,
and 29.6% moderate hypochondriasis. (Refer to Table 1 for the
demographics and clinical ratings on baseline measures by
treatment group; no significant differences were noted between
groups on these measures).
Dropouts
Of the 45 randomized subjects, 6 (25%) of the
24 patients assigned to fluoxetine and 7 (33.3%) of the
21 patients assigned to placebo dropped out before the end of
the acute phase. Comparing drug versus placebo, reasons for
dropout included noncompliance with pills (1/24 vs 1/21),
emotional deterioration (1/24 vs 4/21), noncompliance with
visits (1/24 vs 1/21), moved/never returned (1/24 vs 1/21),
and new troubling physical symptoms (2/24 vs 0/21). In only
2 of the 6 fluoxetine-randomized dropouts was the cause
attributed to the study drug; 1 patient developed gastro-
intestinal distress, and the other developed tachycardia after
starting the drug.
Outcome
Effect of Treatment on Responder/Nonresponder Status
At week 12, fluoxetine was significantly more effective
than placebo in the ITT sample, the minimum-treatment
sample, and the acute-phase completer sample (Table 2). The
responder rate for the ITT sample was nearly twice as great
for those patients randomized to fluoxetine (62.5%) as
compared with placebo (33.3%). This pattern of more
responders in the fluoxetine-treated group versus placebo
was also seen at week 8 but not at week 4. When examining
the subgroup of ITT responders who were virtually free of
hypochondriasis at week 12 (ie, rated as Bvery much
improved[ on the CGI scale), a trend was seen such that
the proportion of hypochondriasis-free patients was 3.5 times
greater in the fluoxetine group than in the placebo group (8/
24 vs 2/21, Fisher exact test P = 0.08). If instead of carrying
the last rating forward, we used the more conservative
imputation method and assume that all patients not rated
were nonresponders, then the ITT responder rate at week 12
would be 14 (58.3%) of 24 for fluoxetine versus 4 (19.0%) of
21 for placebo (W21 = 7.2, P = 0.007).
Effect of Treatment on Secondary
Hypochondriasis-Specific Outcome Measures
When the secondary hypochondriasis scales (CHIC-
OCS, the HIC-Severity, and the Whiteley Index) were evaluated
as continuous measures, the drug-treated group consistently
had greater improvement than the placebo group, but the dif-
ference was at the margin of significance only for the completer
sample on the CHIC-OCS at week 12 (P = 0.05) (Table 3). The
treatment effect size was mild to moderate for the ITT sample
and mild to large for the week 12 completer sample. When
these same measures were evaluated categorically to compare
the proportion of patients who improved at least 25% over
baseline, no significant differences between drug and placebo
groups were noted in the ITT or completer samples. In a post
hoc analysis, we applied the more conservative convention
used in OCD research of requiring the definition of response
to include both a CGI improvement rating of 1 or 2 (ie,
responder) and a dimensional improvement of at least 25% on
the CHIC-OCS; using this approach, the drug-treated group
TABLE 3. Ratings on Secondary Outcome Measures at Week 12 as Compared With Baseline
Continuous Analysis: Percentage Improvement in Scores at Week 12 Compared With Baseline










Measures M SD M SD t df P ES M SD M SD t df P ES
CHIC-OCS 38.2 36.9 22.7 28.1 1.6 43 0.13 0.55 48.8 30.9 26.5 31.6 2.01 30 0.05 0.71
HIC Severity 24.6 25.3 16.8 21.0 1.1 43 0.27 0.37 30.0 24.9 19.9 23.6 1.17 30 0.25 0.43
Whiteley Index 21.3 24.4 13.9 23.1 1.0 43 0.31 0.32 27.0 25.2 20.5 26.0 0.71 30 0.48 0.25
Categorical Analysis: Percentage of Patients Who Improved at Least 25% Over Baseline at Week 12









Outcome n % n % WW2 P n % n % W2 P
CHIC-OCS 16 66.7 10 47.6 1.66 0.20 15 83.3 7 50.0 4.07 0.06 (FET)
HIC Severity Scale 11 45.8 7 33.3 0.73 0.39 10 55.6 5 35.7 1.25 0.27
Whiteley Index 13 54.2 7 33.3 1.97 0.16 12 66.6 7 50.0 0.91 0.34
FET indicates Fisher exact test; ES, effect size.
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was shown to have a greater proportion of responders than
the placebo group in both the ITT sample (14/24 vs 5/21;
W21 = 5.5, P = 0.02) and the completer samples (13/18 vs 3/14;
W21 = 8.1, P < 0.01).
Effect of Baseline Covariates on Responder/Nonresponder
Status
Axis I and II Comorbidity. The effect of treatment on response
status did not depend on Axis I or Axis II comorbidity: there
was no significant interaction between comorbidity measures
and treatment assignment in the logistic regression models for
response. Because patient randomization was stratified based
on comorbidity, Axis I and Axis II comorbidity was equally
distributed across treatment groups.
Other Covariates. Using a logistic regression analysis, other
covariates that might be expected to have an impact on
treatment response were also examined, such as age, sex,
baseline scores on general hypochondriasis (Whiteley, CHIC-
OCS, HIC-Severity), intensity of somatic symptoms (SSI),
depression (BDI, 24-item HAM-D), and anxiety (HAM-A).
None of these covariates modified the effect of treatment,
as no treatment-by-covariate interaction effect on response
was noted.
Effect of Treatment on Psychopathology
No significant differences between the drug and placebo
groups were noted for the ITT or the completer samples on the
continuous measures of depression (BDI and HAM-D), anxiety
(HAM-A), or somatization (SSI).
Relationship Between Fluoxetine Dose, Response Status,
and Dropout
The mean final dose was 51.4 mg (SD, 23.0 mg), and
the median final dosage was 50 mg/d. Maximum dose
reached was 20 mg/d for 23% of sample, 40 mg/d for 27%,
60 mg/d for 23%, and 80 mg/d for 27%. As would be
expected with a flexibly dosed study, no significant relation-
ship was noted between final maximal dose and degree of
symptom improvement. Although a higher dropout rate was
noted among patients whose last dose was 20 mg compared
with higher doses (80% vs 11.8% dropout), this is likely due
to the fact that patients were most likely to discontinue during
the first few weeks of the study when the dose was lowest.
Maintenance Phase
Of the 18 patients (14 drug/4 placebo) whowere rated as
responders after completing 12 weeks of treatment, 15 agreed
to enter the double-masked maintenance phase (11 on
fluoxetine and 4 on placebo). Of the 3 fluoxetine responders
at week 12 who did not continue into the maintenance phase, 2
were feeling so much better that they felt further participation
in the study was not needed and 1 responder had to be
withdrawn from the study due to a pharmacy error in which the
patient was mistakenly advanced to the discontinuation phase.
During the maintenance period, 2 subjects dropped out before
week 24 (1 for homicidal thoughts on placebo and 1 for
noncompliance on active drug). Of the 13 who completed
24 weeks of treatment, 10 of 10 subjects on drug and 1 of 3
subjects on placebo maintained their response. For the ITT
sample, at the end of the maintenance phase, there continued
to be significantly more responders in the fluoxetine group (n =
13/24 [54.2%]) than in the placebo group (n = 5/21 [23.8%])
(W21 = 4.4, P = 0.04). Using a more conservative imputation
method, the ITT responder rate at week 24 would be 10
(41.7%) of 24 for fluoxetine versus 1 (4.8%) of 21 for
placebo (W21 = 8.3, P = 0.004). Also notable is that more
patients randomized to fluoxetine remained in the study to
week 24 (10/24, 41.7%) than patients randomized to placebo
(3/21, 14.3%) (W21 = 4.3, P = 0.04). For the ITT sample at
week 24, patients randomized to fluoxetine showed greater
percentage improvement in hypochondriasis compared with
baseline than those randomized to placebo on the HIC
Severity Scale (30.1 [SD, 30.3] vs 14.9 [SD, 19.6]; t = 2.0,
P = 0.05, effect size d = 0.6).
Discontinuation Phase
Of the 11 patients (10 drug/1 placebo) with a sustained
response at week 24, 1 in the placebo group discontinued
after the week 24 rating, leaving 10 subjects to enter the
double-masked discontinuation phase, all of whom had been
initially randomized to drug. Of these 10 subjects, 6
continued on drug, and 4 were switched to placebo. Of the
6 maintained on drug, 4 sustained their response to week 36,
1 became a nonresponder, and 1 was lost to follow-up. Of the
4 initially on drug who were switched to placebo at week 24,
3 maintained their response to week 36 and 1 was a
nonresponder. In sum, 7 of the 10 patients sustained their
response. Although there was no significant difference in
ability to sustain a response between those maintained on
fluoxetine and those switched to placebo, larger sample sizes
are needed to assess this adequately.
DISCUSSION
This hypochondriasis efficacy study examined short-
term efficacy to 3 months and durability of efficacy among
responders after maintenance treatment to 6 months. Con-
clusions about durability after controlled drug discontinuation
could not be reasonably assessed, given the small sample of
patients who entered the final 3-month phase of the study. On
the primary outcome measure of clinical global improvement,
fluoxetine was more effective than placebo, and this improve-
ment was sustained over a 6-month interval. Given the
distress, disability, and high utilization rate of medical
services by hypochondriacal patients, identification of an
effective pharmacological treatment should have a valuable
public health impact.
At the primary end point of week 12, the proportion of
responders to fluoxetine compared with placebo was signifi-
cant for the completer and minimum-treatment samples and
at the margin of significance (P = 0.05) for the ITT sample.
In this placebo-controlled study, 62.5% of the ITT sample
and 77.8% of the acute-phase completers were rated as
responders at week 12. These controlled results confirm SSRI
efficacy as had been suggested by prior uncontrolled open-
label series of SSRIs for hypochondriasis.10,20–22 In this
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controlled study, patients with and without Axis I or Axis II
comorbidity were equally likely to benefit. It is not possible
to compare the results of this double-blind study with an
earlier double-masked, placebo-controlled paroxetine study
for hypochondriasis9 because of differences in definition of
study responders.
The degree of improvement in hypochondriasis was
moderate on average. Inability to demonstrate a significant
treatment effect on the continuous measures at week 12 for
the ITT sample likely reflects both the modest effect size and
the small sample size. Self-report measures (such as the
Whiteley Index) may also be less sensitive than clinician-
administered instruments (such as the CHIC-OCS or HIC
Severity Scale), as there was a significant improvement noted
on the CHIC-OCS for the week 12 completer sample and on
the HIC Severity Scale for the week 24 ITT sample but not on
the Whiteley Index at either time point. Similarly modest
degrees of improvement on continuous measures have been
reported after pharmacotherapy with SSRIs for other disor-
ders characterized by marked obsessionality, as in OCD.23
Studies with larger sample sizes are needed to address theses
issues.
Notable is that significantly more patients on fluoxetine
reached the week 24 end point without dropping out and that
only those randomized to fluoxetine in the acute phase
sustained a long-term response during the follow-up to week
36. Among the 13 patients assessed at week 24, all 10 of the
10 remaining fluoxetine-randomized patients continued to be
rated as responders, whereas only 1 of the 3 remaining
placebo-randomized patients maintained a favorable
response. The study results also suggest that improvement
in hypochondriasis for the fluoxetine group increased over the
6 months, as shown by the larger effect size for the
percentage of improvement from baseline on the HIC
Severity Scale at week 24 compared with that observed at
week 12. None of the placebo-treated patients continued to
week 36, whereas 10 of the original fluoxetine-randomized
patients continued to week 36 (of whom 4 of 6 maintained on
drug and 3 of 4 switched to placebo sustained their
improvement). Although the sample size of study completers
is quite small, these results do suggest that fluoxetine
treatment resulted in sustained improvement. Although it is
encouraging to note that 3 of the 4 patients who were
switched to placebo during the double-blind discontinuation
phase maintained their response, no conclusions can be
drawn about the durability of response when patients stop
fluoxetine after 6 months, given the small sample size.
The fluoxetine- and placebo-treated groups had com-
parable rates of study withdrawal, indicating general toler-
ance of fluoxetine. Hypochondriacal patients who typically
are wary of taking medication should be reassured by this
study to learn that fluoxetine was well tolerated.
Although the design of this study has many strengths
(randomized, placebo-controlled, stratified by comorbidity, IE
ratings, double-masked maintenance, and discontinuation
periods), the primary limitation of this study is the small
sample size, which limits the power to detect statistical
significance on the continuous measures. A second limitation
is that the assessments at weeks 24 and 36 were conducted
only on patients who had a sufficient improvement to enter
the maintenance and discontinuation phases; it would have
been preferable to call back all randomized subjects for
evaluation at these intervals. Third, because of the flexible
dosing, we cannot determine whether higher doses are more
or less effective than lower doses. Fourth, it would have been
valuable to have both patients and IEs guess the treatment to
which they had been randomized; this would enable an
assessment of inadvertent unmasking. Fifth, the results from
this study may not be generalizable to all patients with
hypochondriasis. The patients enrolled in this study had to
have sufficient insight to recognize that their concerns about
illness were excessive; otherwise, they would not have
responded to the public advertisements or their primary care
physician’s recommendations and volunteered to participate
in a treatment study for a psychiatric disorder. It cannot be
inferred therefore that other patients with hypochondriasis
who might not wish to see a psychiatrist and who might have
lesser degrees of insight would respond as well to fluoxetine
as occurred in this study sample. Finally, it would have been
valuable to have included a measure in this study that
assessed health care utilization to determine whether a
reduction in hypochondriasis was associated with less health
care use and expenditures.
In sum, psychiatrists and primary care physicians
should be aware that fluoxetine seems to be a moderately
efficacious and well-tolerated treatment for hypochondriasis.
A trial that lasts at least 12 weeks is recommended to assess
response. Although the data from this trial suggest that
treatment for 6 months may be sufficient and result in
sustained improvement, conclusions cannot be drawn without
a larger sample size and longer follow-up interval.
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